The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Open accessAbstract
A screen identifies a drug that specifically kills glycolysis-dependent cancer cells by inhibiting glucose uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Dependence of VHL-deficient cells on glycolysis These data suggest that renal cells with defective VHL, like a range of other cancers, are highly dependent on aerobic glycolysis for energy production (5, 15, 16).”
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
MOTZER, R. J., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 603
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Gene Signatures of Progression and Metastasis in Renal Cell Cancer
Jones, J., Otu, H., Spentzos, D., Kolia, S., Inan, M., Beecken, W. D., Fellbaum, C., Gu, X., Joseph, M., Pantuck, A. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2225 · Cited by 447
A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
Turcotte, S., Chan, D. A., Sutphin, P. D., Hay, M. P., Denny, W. A., & Giaccia, A. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.004 · Cited by 251
Self-citationErythrocyte Glut1 Triggers Dehydroascorbic Acid Uptake in Mammals Unable to Synthesize Vitamin C
Montel-Hagen, A., Kinet, S., Manel, N., Mongellaz, C., Prohaska, R., Battini, J.-L., Delaunay, J., Sitbon, M., & Taylor, N. (2008) · Cell · doi:10.1016/j.cell.2008.01.042 · Cited by 243
GLUT1 deficiency syndrome – 2007 update
Klepper, J., & Leiendecker, B. (2007) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2007.00707.x · Cited by 240
Salas-Burgos, A., Iserovich, P., Zuniga, F., Vera, J. C., & Fischbarg, J. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.047886 · Cited by 198
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195
A mouse model for Glut-1 haploinsufficiency
Wang, D., Pascual, J. M., Yang, H., Engelstad, K., Mao, X., Cheng, J., Yoo, J., Noebels, J. L., & De Vivo, D. C. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl032 · Cited by 185
Garcia, J. C., Strube, M., Leingang, K., Keller, K., & Mueckler, M. M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42581-1 · Cited by 169
Autosomal dominant Glut‐1 deficiency syndrome and familial epilepsy
Brockmann, K., Wang, D., Korenke, C. G., Von Moers, A., Ho, Y., Pascual, J. M., Kuang, K., Yang, H., Ma, L., Kranz‐Eble, P., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1222 · Cited by 163
Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116
Differential expression of facilitative glucose transporters in normal and tumour kidney tissues
Suganuma, N., Segade, F., Matsuzu, K., & Bowden, D. W. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06765.x · Cited by 69
Inhibitor Binding in the Human Renal Low- and High-Affinity Na+/Glucose Cotransporters
Pajor, A. M., Randolph, K. M., Kerner, S. A., & Smith, C. D. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129825 · Cited by 63
Hay, M. P., Turcotte, S., Flanagan, J. U., Bonnet, M., Chan, D. A., Sutphin, P. D., Nguyen, P., Giaccia, A. J., & Denny, W. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901457w · Cited by 62
Self-citationTargeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells
Sutphin, P. D., Chan, D. A., Li, J. M., Turcotte, S., Krieg, A. J., & Giaccia, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0604 · Cited by 36
Self-citationCowey, C. L., Fielding, J. R., & Rathmell, W. K. (2009) · Urology · doi:10.1016/j.urology.2009.06.105 · Cited by 29
Rathmell, W. K., Lee, C. M., & Rini, B. I. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3280ad4388 · Cited by 13
Cited by
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,115
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 929
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Metadata
- Authors
- Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., Bonnet, M., Flanagan, J. U., Bouley, D. M., Graves, E. E., Denny, W. A., Hay, M. P., & Giaccia, A. J.
- Venue
- Science Translational Medicine
- Published
- 2011-08-03
- Volume
- 3
- Issue
- 94
- Pages
- 94ra70-94ra70
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2107975811
- Cited by
- 557
- References
- 30
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.